期刊
NEURODEGENERATIVE DISEASE MANAGEMENT
卷 2, 期 2, 页码 221-232出版社
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.12.6
关键词
-
资金
- NIH [R01 NS031373-15]
- rapeutics, Janssen Pharmaceutica (Beerse, Belgium)
- Michael J Fox Foundation and Vanderbilt University
Parkinson's disease (PD) is a progressive neurological disorder predominantly characterized by motor symptoms including bradykinesia and resting tremor. The gold standard of treatment for PD remains dopamine replacement therapy, which eventually fails due to continued progression of the disease and the development of debilitating side effects. Recent breakthroughs are providing the first major advances in the development of fundamentally new pharmacological strategies for the treatment of PD that do not rely on dopamine replacement strategies, but rather aim to reduce the overactive indirect pathway within the basal ganglia. In this article, we will review the role of metabotropic glutamate receptors within the basal ganglia and discuss the potential for modulation of metabotropic glutamate receptors as a treatment for PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据